{"success":true,"data":{"pressRelease":{"id":"4824","rtpr_id":"nACSwx1B5a","ticker":"IMRN","exchange":"NASDAQ","all_tickers":["IMRN","IMC"],"title":"Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00","author":"ACCESSWIRE","published_at":"2026-04-22T13:00:01.738Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April\n22, 2026 / Emerging Growth Research today released a Flash Report on Immuron\n(Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its\n12-month price target to $4.00 (from $3.90), representing significant upside\nfrom the current share price of $0.9268 as of April 21, 2026.\n\nThe Flash Report highlights Immuron's continued revenue growth, expanding\ncommercial footprint, and progress within its clinical development pipeline.\n\nKey Highlights:\n*\nDouble-Digit Revenue Growth: Immuron reported global product revenue of AUD\n$1.5 million for 3Q FY2026, representing a 16% year-over-year increase. Growth\nwas primarily driven by increased sales of Travelan(®) across Australia and\nthe United States.\n*\nStrong Core Market Performance: Year-over-year revenue growth in Australia and\nthe U.S. reached 15% and 1%, respectively (in AUD), with stronger underlying\nU.S. growth when measured in USD due to foreign exchange impacts.\n*\nRapid Expansion in Canada: While still a smaller market, Canadian revenue\ndemonstrated strong sequential growth, increasing 82% quarter-over-quarter,\nsupported by ongoing brand awareness initiatives.\n*\nRevenue-Generating Commercial Products: Immuron continues to generate revenue\nfrom its marketed products in Australia, the U.S., and Canada, helping offset\nclinical development costs. A third product was launched in Australia in\nDecember 2025.\n*\nPromising Clinical Pipeline: The Company is advancing two key candidates:\n*\nIMM-124E (Travelan(®)) for travelers' diarrhea\n*\nIMM-529 for Clostridioides difficile (C. difficile) infections, with FDA\nclearance to proceed into Phase 2 clinical trials\n*\nStrategic Partnering Opportunities: Immuron is actively seeking partners to\nadvance both IMM-124E and IMM-529 through later-stage development.\n*\nCompelling Valuation: Based on an updated peer group EV/Revenue multiple of\n6.22x, Emerging Growth Research derives an enterprise valuation of\napproximately $33.3 million, supporting the increased $4.00 price target.\n\nFor a copy of the full Flash Report, please visit:\n\nhttps://emerginggrowth.com/wp-content/uploads/2026/04/Immuron-Flash-Report-2026-04-22.pdf\n\nOr\n\nhttps://www.emerginggrowth.com/profile/imrn/ (on the right side of the page as\nyou scroll down)\n\nAbout Immuron\nImmuron Limited is a commercial and clinical-stage biopharmaceutical company\nfocused on developing oral immunotherapies for the treatment of\ngastrointestinal infections. The Company's proprietary platform utilizes\npolyclonal antibodies derived from hyperimmune bovine colostrum. Immuron\nmarkets products in Australia, the United States, and Canada, while advancing\na pipeline targeting infectious diseases with significant unmet medical needs.\n\nAbout Emerging Growth Research\nEmerging Growth Research is an independent equity research firm providing\ninstitutional-quality analysis on emerging and growth-stage companies. The\nfirm delivers ongoing research coverage - including Flash Reports on material\ndevelopments - to enhance transparency and broaden market awareness for\ncompanies participating in the Emerging Growth Conference platform.\n\nContact:\nEmerging Growth Research\nResearch@EmergingGrowth.com\nwww.EmergingGrowth.com\n\nForward-Looking Statements\nThis press release contains forward-looking statements concerning business\noperations, financial performance, and future expectations. These statements\nare subject to risks and uncertainties, and actual results may differ\nmaterially from those projected. Investors are encouraged to review all risk\nfactors and disclosures before making investment decisions.\n(https://app.accessnewswire.com/imagelibrary/8740e7ca-b75a-4ec5-9df9-a9253e4ad6e5/egr-logo-for-accesswire.png)\nSOURCE: Immuron Limited\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-flash-report-on-immuron-maintains-b-1159813)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSwx1B5a","title":"Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00","author":"ACCESSWIRE","ticker":"IMRN","created":"2026-04-22T13:00:01.738Z","tickers":["IMRN","IMC"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / April\n22, 2026 / Emerging Growth Research today released a Flash Report on Immuron\n(Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its\n12-month price target to $4.00 (from $3.90), representing significant upside\nfrom the current share price of $0.9268 as of April 21, 2026.\n\nThe Flash Report highlights Immuron's continued revenue growth, expanding\ncommercial footprint, and progress within its clinical development pipeline.\n\nKey Highlights:\n*\nDouble-Digit Revenue Growth: Immuron reported global product revenue of AUD\n$1.5 million for 3Q FY2026, representing a 16% year-over-year increase. Growth\nwas primarily driven by increased sales of Travelan(®) across Australia and\nthe United States.\n*\nStrong Core Market Performance: Year-over-year revenue growth in Australia and\nthe U.S. reached 15% and 1%, respectively (in AUD), with stronger underlying\nU.S. growth when measured in USD due to foreign exchange impacts.\n*\nRapid Expansion in Canada: While still a smaller market, Canadian revenue\ndemonstrated strong sequential growth, increasing 82% quarter-over-quarter,\nsupported by ongoing brand awareness initiatives.\n*\nRevenue-Generating Commercial Products: Immuron continues to generate revenue\nfrom its marketed products in Australia, the U.S., and Canada, helping offset\nclinical development costs. A third product was launched in Australia in\nDecember 2025.\n*\nPromising Clinical Pipeline: The Company is advancing two key candidates:\n*\nIMM-124E (Travelan(®)) for travelers' diarrhea\n*\nIMM-529 for Clostridioides difficile (C. difficile) infections, with FDA\nclearance to proceed into Phase 2 clinical trials\n*\nStrategic Partnering Opportunities: Immuron is actively seeking partners to\nadvance both IMM-124E and IMM-529 through later-stage development.\n*\nCompelling Valuation: Based on an updated peer group EV/Revenue multiple of\n6.22x, Emerging Growth Research derives an enterprise valuation of\napproximately $33.3 million, supporting the increased $4.00 price target.\n\nFor a copy of the full Flash Report, please visit:\n\nhttps://emerginggrowth.com/wp-content/uploads/2026/04/Immuron-Flash-Report-2026-04-22.pdf\n\nOr\n\nhttps://www.emerginggrowth.com/profile/imrn/ (on the right side of the page as\nyou scroll down)\n\nAbout Immuron\nImmuron Limited is a commercial and clinical-stage biopharmaceutical company\nfocused on developing oral immunotherapies for the treatment of\ngastrointestinal infections. The Company's proprietary platform utilizes\npolyclonal antibodies derived from hyperimmune bovine colostrum. Immuron\nmarkets products in Australia, the United States, and Canada, while advancing\na pipeline targeting infectious diseases with significant unmet medical needs.\n\nAbout Emerging Growth Research\nEmerging Growth Research is an independent equity research firm providing\ninstitutional-quality analysis on emerging and growth-stage companies. The\nfirm delivers ongoing research coverage - including Flash Reports on material\ndevelopments - to enhance transparency and broaden market awareness for\ncompanies participating in the Emerging Growth Conference platform.\n\nContact:\nEmerging Growth Research\nResearch@EmergingGrowth.com\nwww.EmergingGrowth.com\n\nForward-Looking Statements\nThis press release contains forward-looking statements concerning business\noperations, financial performance, and future expectations. These statements\nare subject to risks and uncertainties, and actual results may differ\nmaterially from those projected. Investors are encouraged to review all risk\nfactors and disclosures before making investment decisions.\n(https://app.accessnewswire.com/imagelibrary/8740e7ca-b75a-4ec5-9df9-a9253e4ad6e5/egr-logo-for-accesswire.png)\nSOURCE: Immuron Limited\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-flash-report-on-immuron-maintains-b-1159813)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-04-22T13:00:01.793372794Z","server_sent_at_ms":1776862801793},"received_at":"2026-04-22T13:00:01.845Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/emerging-growth-research-releases-flash-report-on-immuron-maintains-b-1159813"},"analysis":{"id":"3436","press_release_id":"4824","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Emerging Growth Research maintained a Buy-Extended rating on Immuron and raised its 12-month price target to $4.00, citing double-digit revenue growth and pipeline progress.\n\nThe report highlighted 3Q FY2026 revenue of AUD $1.5 million, a 16% year-over-year increase, driven primarily by sales of Travelan in Australia and the U.S., while Canadian revenue grew 82% quarter-over-quarter.\n\nOn the clinical front, the company received FDA clearance for IMM-529 to proceed into Phase 2 trials for C. difficile infections.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Analyst targets 330% upside backed by 16% revenue growth and Phase 2 clearance."},"keyFigures":{"revenue":"AUD $1.5 million","revenueYoy":"16%","customDimensions":{"price_target_new":"$4.00","price_target_old":"$3.90","canada_qoq_growth":"82%","current_share_price":"$0.9268","enterprise_valuation":"$33.3 million","peer_ev_revenue_multiple":"6.22x"}},"quotedText":"Based on an updated peer group EV/Revenue multiple of 6.22x, Emerging Growth Research derives an enterprise valuation of approximately $33.3 million, supporting the increased $4.00 price target.","namedEntities":{"people":[],"products":["Travelan","IMM-124E","IMM-529"],"companies":[{"name":"Emerging Growth Research","relationship":"analyst"},{"name":"Immuron Limited","ticker":"IMRN"}],"dollarAmounts":[{"amount":"$4.00","context":"new 12-month price target"},{"amount":"$3.90","context":"previous 12-month price target"},{"amount":"$0.9268","context":"current share price as of April 21, 2026"},{"amount":"$33.3 million","context":"implied enterprise valuation"},{"amount":"AUD $1.5 million","context":"3Q FY2026 global product revenue"}]},"materialImpact":{"score":3,"reasoning":"Analyst report raising price target and highlighting positive operational metrics (16% revenue growth, Phase 2 clearance) is encouraging, but as third-party commentary, it carries less weight than a primary company filing."},"tickerRelevance":{"others":[],"primary":"IMRN"},"eventTypeSecondary":["clinical_trial"]},"event_type":"other","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":3,"narrative":"Emerging Growth Research maintained a Buy-Extended rating on Immuron and raised its 12-month price target to $4.00, citing double-digit revenue growth and pipeline progress.\n\nThe report highlighted 3Q FY2026 revenue of AUD $1.5 million, a 16% year-over-year increase, driven primarily by sales of Travelan in Australia and the U.S., while Canadian revenue grew 82% quarter-over-quarter.\n\nOn the clinical front, the company received FDA clearance for IMM-529 to proceed into Phase 2 trials for C. difficile infections.","key_figures":{"revenue":"AUD $1.5 million","revenueYoy":"16%","customDimensions":{"price_target_new":"$4.00","price_target_old":"$3.90","canada_qoq_growth":"82%","current_share_price":"$0.9268","enterprise_valuation":"$33.3 million","peer_ev_revenue_multiple":"6.22x"}},"named_entities":{"people":[],"products":["Travelan","IMM-124E","IMM-529"],"companies":[{"name":"Emerging Growth Research","relationship":"analyst"},{"name":"Immuron Limited","ticker":"IMRN"}],"dollarAmounts":[{"amount":"$4.00","context":"new 12-month price target"},{"amount":"$3.90","context":"previous 12-month price target"},{"amount":"$0.9268","context":"current share price as of April 21, 2026"},{"amount":"$33.3 million","context":"implied enterprise valuation"},{"amount":"AUD $1.5 million","context":"3Q FY2026 global product revenue"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T17:06:18.723Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.204Z"}},"durationMs":66197,"modelName":"glm-4.7"}}